The connection between multiple sclerosis and Epstein-Barr virus (EBV) is strengthening, according to a paper published this week in JAMA Neurology by a team of international researchers, including a ...
Pierre Fabre Pharmaceuticals, Inc., announces the U.S. Food and Drug Administration (FDA) has agreed to Type A meeting for the biologic license application for tabelecleucel, an allogeneic T-cell ...
Genomics, a science-led techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, today presented new ...
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in ...
Bavarian Nordic AS (BVNKF) reported strong financial results for 2025, with a revenue of 6.2 billion Danish krona and an EBITDA margin of 28%. The company experienced a 30% growth in its travel health ...
Immunic Therapeutics was granted a patent in Europe that protects all dosing regimens of its MS therapy vidofludimus calcium through 2038.
Good day, and thank you for standing by. Welcome to the Bavarian Nordic 2025 Annual Report. [Operator Instructions] Please be advised today's conference is being recorded. I'd now like to hand the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results